Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
CSPC PHARMA (01093.HK) In-house SYS 6010 Included Again in China Breakthrough Therapy Designation List
Recommend 10 Positive 14 Negative 5 |
||||
|
||||
|
CSPC PHARMA (01093.HK) announced that its self-developed SYS 6010 (an EGFR-targeting humanized monoclonal antibody-drug conjugate) has recently been included again by the National Medical Products Administration in the Breakthrough Therapy Designation list. The proposed indication is monotherapy for patients with locally advanced or metastatic esophageal squamous cell carcinoma who have previously failed platinum-containing chemotherapy and immunotherapy. (sl/da) Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
